MilliporeSigma™ Calbiochem™ InSolution™ Batimastat

Description

A Marimastat type of peptidyl hydroxamate-based inhibitor that potently inhibits a broad-spectrum of metalloproteinases

A Marimastat (Cat. No. 444289) type of peptidyl hydroxamate-based inhibitor that potently inhibits a broad-spectrum of metalloproteinases, including MMP-1, MMP-2, MMP-3/stromelysin, MMP-7/matrilysin, MMP-9, δMT1 (MMP-14 without TM domain), ADAM8, and ADAM17/TACE (IC₅₀ = 3, 4, 20, 6, 4, 2.08, 51.3, and 19 nM, respectively), by targeting both the substrate binding site and the active-site Zn²⁺, while being much less potent toward ACE (Angiotensin Converting Enzyme) or α-secretase (IC₅₀ = 1.6 and 3.3μM, respectively). Batimastat is widely used in studying the involvement of MMPs in cancinogenesis and non-cancer pathological processes both in cultures in vitro and in animals in vivo .

Specifications

• Formulation: A 25 mM (2mg/168μL) sterile-filtered solution of Batimastat in DMSO.
• Description: 97% by HPLC
• Target Proteins: MMPs
• Molecular Formula: C₂₃H₃₁N₃O₄S₂
• Formula Weight: 477.6g/mol
• Content And Storage: Avoid Freeze-Thaw Cycles, Hygroscopic, Protect from Light
• Form: Liquid
• Quantity: 2 mg